Search results
Results from the WOW.Com Content Network
Astressin-B is a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of adrenocorticotropic hormone and cortisol. [1] It reduces the synthesis of adrenocorticotropic hormone and improves the sexual drive of rats under stressing conditions. [2] Astressin-B is able to delay the emptying of solid food in mice. [3]
A Corticotropin-releasing hormone antagonist (CRH antagonist) is a specific type of receptor antagonist that blocks the receptor sites for corticotropin-releasing hormone, also known as corticotropin-releasing factor (CRF), which synchronizes the behavioral, endocrine, autonomic, and immune responses to stress by controlling the hypothalamic-pituitary-adrenal axis (HPA axis). [1]
Top Prescription Weight Loss Pills. Anti-obesity medications (AOMs) date back to the 1940s — well before modern regulations from the FDA (U.S. Food and Drug Administration) (FDA) were in place ...
For the first twelve weeks of use, it is advised to take the ormeloxifene pill twice per week. [6] From the thirteenth week on, it is taken once per week. [6] [7] The consensus is that backup protection in the first month is a cautious but sensible choice. A standard dose is 30 mg weekly, but 60 mg loading doses can reduce pregnancy rates by 38 ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [31] [28] [32] [33] It is specifically used for cancer that is HER2 receptor positive. [31] It may be used by itself or together with other chemotherapy medication. [31]
Rhino pills and other non-prescription supplements aren’t regulated by the U.S. Food and Drug Administration (FDA) like medications are, and there’s rarely much science to back their claims.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
In January 2012, it became the first Hedgehog pathway inhibitor to be approved by the FDA for the treatment of any cancer. Vismodegib is currently used for the treatment of metastatic basal cell carcinoma (BCC) in adults. It is also used for treating patients with locally advanced BCC who are not candidates for surgery or radiation therapy. [34]